Apollon Wealth Management LLC Buys 1,929 Shares of Boston Scientific Corporation $BSX

Apollon Wealth Management LLC increased its stake in Boston Scientific Corporation (NYSE:BSX) by 8.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 24,826 shares of the medical equipment provider’s stock after buying an additional 1,929 shares during the quarter. Apollon Wealth Management LLC’s holdings in Boston Scientific were worth $2,667,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. 1248 Management LLC bought a new stake in Boston Scientific in the first quarter worth $26,000. Y.D. More Investments Ltd bought a new stake in Boston Scientific in the first quarter worth $27,000. Sound Income Strategies LLC lifted its position in Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 120 shares during the last quarter. Oliver Lagore Vanvalin Investment Group bought a new stake in Boston Scientific in the second quarter worth $37,000. Finally, Activest Wealth Management lifted its position in Boston Scientific by 6,216.7% in the first quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider’s stock worth $38,000 after buying an additional 373 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Insider Transactions at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares in the company, valued at approximately $2,469,268. This trade represents a 42.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $5,231,500.00. Following the transaction, the executive vice president owned 178,342 shares in the company, valued at approximately $18,659,923.46. This represents a 21.90% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 174,214 shares of company stock worth $17,972,457. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Stock Performance

Shares of Boston Scientific stock opened at $95.41 on Monday. The firm has a market cap of $141.38 billion, a P/E ratio of 56.79, a P/E/G ratio of 2.30 and a beta of 0.61. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a 12 month low of $80.64 and a 12 month high of $109.50. The stock’s fifty day moving average price is $101.98 and its 200-day moving average price is $101.87.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business’s revenue for the quarter was up 22.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities research analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

BSX has been the subject of several research analyst reports. Leerink Partners lifted their target price on Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 1st. Canaccord Genuity Group lifted their target price on Boston Scientific from $131.00 to $132.00 and gave the stock a “buy” rating in a research report on Wednesday, October 1st. Jefferies Financial Group reiterated a “hold” rating on shares of Boston Scientific in a research report on Monday, July 21st. Robert W. Baird lifted their target price on Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 1st. Finally, Wall Street Zen upgraded Boston Scientific from a “hold” rating to a “buy” rating in a research report on Saturday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, Boston Scientific currently has a consensus rating of “Buy” and a consensus target price of $120.71.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.